Clinical TrialsThe Phase 3 SELECT-MDS-1 study successfully passed a predetermined interim futility analysis regarding the complete response rate, conducted by an Independent Data Monitoring Committee.
Enrollment MilestonesSyros announced the enrollment of the required 190 participants for the SELECT-MDS-1 Phase 3 clinical trial, which is essential for analyzing the primary complete response endpoint and submitting a New Drug Application.
Regulatory DesignationsThe FDA recently granted Fast Track Designation to tamibarotene in combination with venetoclax and azacitidine.